Lexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation

Dow Jones

Jul 31, 2025

By Chris Wack

Lexeo Therapeutics shares were 17% higher, at $4.78, after the company said that the Food and Drug Administration has granted breakthrough therapy designation to gene therapy LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich's ataxia.

The clinical stage genetic medicine company said LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, intended to enable earlier patient access to therapies with expedited clinical development timelines.

To date, 17 participants have been treated across two trials, and Lexeo is currently enrolling a prospective natural history study, which will serve as a concurrent external control arm for the registrational study.

The company expects to initiate the registrational study by early 2026 and is actively working with FDA to finalize the statistical analysis plan.

Breakthrough Therapy designation is intended to accelerate the development and review of investigational therapies that aim to treat serious or life-threatening diseases and where preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over available alternatives.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 30, 2025 12:46 ET (16:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2555264200"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555264200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555264200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555264200","market":"sh","top_or_hot":-1,"title":"Lexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> shares were 17% higher, at $4.78, after the company said that the Food and Drug Administration has granted breakthrough therapy designation to gene therapy LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich's ataxia. \n</p>\n<p>\n  The clinical stage genetic medicine company said LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, intended to enable earlier patient access to therapies with expedited clinical development timelines. \n</p>\n<p>\n  To date, 17 participants have been treated across two trials, and Lexeo is currently enrolling a prospective natural history study, which will serve as a concurrent external control arm for the registrational study. \n</p>\n<p>\n  The company expects to initiate the registrational study by early 2026 and is actively working with FDA to finalize the statistical analysis plan. \n</p>\n<p>\n  Breakthrough Therapy designation is intended to accelerate the development and review of investigational therapies that aim to treat serious or life-threatening diseases and where preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over available alternatives. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 30, 2025 12:46 ET (16:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexeo Therapeutics Shares Rise as Gene Therapy Granted Breakthrough Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-31 00:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> shares were 17% higher, at $4.78, after the company said that the Food and Drug Administration has granted breakthrough therapy designation to gene therapy LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich's ataxia. \n</p>\n<p>\n  The clinical stage genetic medicine company said LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, intended to enable earlier patient access to therapies with expedited clinical development timelines. \n</p>\n<p>\n  To date, 17 participants have been treated across two trials, and Lexeo is currently enrolling a prospective natural history study, which will serve as a concurrent external control arm for the registrational study. \n</p>\n<p>\n  The company expects to initiate the registrational study by early 2026 and is actively working with FDA to finalize the statistical analysis plan. \n</p>\n<p>\n  Breakthrough Therapy designation is intended to accelerate the development and review of investigational therapies that aim to treat serious or life-threatening diseases and where preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over available alternatives. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 30, 2025 12:46 ET (16:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2555264200","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555264200","pubTimestamp":1753893960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lexeo Therapeutics shares were 17% higher, at $4.78, after the company said that the Food and Drug Administration has granted breakthrough therapy designation to gene therapy LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich's ataxia.The clinical stage genetic medicine company said LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, intended to enable earlier patient access to therapies with expedited clinical development timelines.To date, 17 participants have been treated across two trials, and Lexeo is currently enrolling a prospective natural history study, which will serve as a concurrent external control arm for the registrational study.The company expects to initiate the registrational study by early 2026 and is actively working with FDA to finalize the statistical analysis plan.Breakthrough Therapy designation is intended to accelerate the developm","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LXEO":"Lexeo Therapeutics"},"translate_title":"基因疗法获得突破性称号，Lexeo Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXEO":1},"content_text":"By Chris Wack \n\n\n \n\n\nLexeo Therapeutics shares were 17% higher, at $4.78, after the company said that the Food and Drug Administration has granted breakthrough therapy designation to gene therapy LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich's ataxia. \n\n\n  The clinical stage genetic medicine company said LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, intended to enable earlier patient access to therapies with expedited clinical development timelines. \n\n\n  To date, 17 participants have been treated across two trials, and Lexeo is currently enrolling a prospective natural history study, which will serve as a concurrent external control arm for the registrational study. \n\n\n  The company expects to initiate the registrational study by early 2026 and is actively working with FDA to finalize the statistical analysis plan. \n\n\n  Breakthrough Therapy designation is intended to accelerate the development and review of investigational therapies that aim to treat serious or life-threatening diseases and where preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over available alternatives. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 30, 2025 12:46 ET (16:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}